Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin

Tsoukalas,N.; Tolia,M.; Lypas,G.; Panopoulos,C.; Barbounis,V.; Koumakis,G.; Efremidis,A.

doi:10.3892/ol.2013.1646

Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin

Authors:
- N. Tsoukalas
- M. Tolia
- G. Lypas
- C. Panopoulos
- V. Barbounis
- G. Koumakis
- A. Efremidis
View Affiliations

Affiliations: 2nd Department of Medical Oncology, ‘Agios Savvas’ Anticancer Hospital, Athens, Ampelokipi 11524, Greece
Published online on: October 29, 2013 https://doi.org/10.3892/ol.2013.1646
Pages: 47-49

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study describes a rare case of a mesenteric liposarcoma that resulted in a complete remission (CR) following treatment with trabectedin (Yondelis®). The patient presented with abdominal pain and fever. An abdominal mass was identified that corresponded to a mixed‑type high‑grade mesenteric liposarcoma with wide areas of necrosis, areas of dedifferentiation and features of a leiomyosarcoma. Three months after the removal of the first mass, the patient underwent a second laparotomy, followed by treatment with doxorubicin and ifosfamide. Subsequently, the patient was started on therapy with trabectedin and a CR was noted following only four cycles of therapy. The best responses that are reported in the literature for cases of liposarcoma treated with trabectedin are mostly for liposarcomas of the myxoid/round cell type and are mainly partial responses. In the present study, trabectedin was used for the treatment of a mesenteric liposarcoma of mixed morphological features and a CR was achieved.

View Figures

View References

1	Conyers R, Young S and Thomas DM: Liposarcoma: Molecular genetics and therapeutics. Sarcoma. 2011:4831542011. View Article : Google Scholar : PubMed/NCBI
2	Dei Tos AP: Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol. 4:252–266. 2000.PubMed/NCBI
3	Jain SK, Mitra A, Kaza RCM and Malagi S: Primary mesenteric liposarcoma: an unusual presentation of a rare condition. J Gastrointest Oncol. 3:147–150. 2012.
4	Neuhaus SJ, Barry P, Clark MA, et al: Surgical management of primary and recurrent retroperitoneal liposarcoma. Br J Surg. 92:246–252. 2005. View Article : Google Scholar : PubMed/NCBI
5	Hasegawa T, Seki K, Hasegawa F, et al: Dedifferentiatted liposarcoma of the retroperitoneum and the mesentery: varied growth patterns and histological grades - a clinicopathological study of 32 cases. Hum Pathol. 31:717–727. 2000. View Article : Google Scholar
6	Skubitz KM and D’Adamo DR: Sarcoma. Mayo ClinProc. 82:1409–1432. 2007. View Article : Google Scholar
7	Lucas DR, Nascimento AG, Sanjay BK and Rock MG: Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol. 102:677–683. 1994.
8	Henricks WH, Chu YC, Goldblum JR and Weiss SW: Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 21:271–281. 1997. View Article : Google Scholar
9	Russell MJ, Flynt FL, Harroff AL and Fadere O: Dedifferentiated liposarcoma of the retroperitoneum with extensive leiomyosarcomatous differentiation and human chorionic gonadotropin production. Sarcoma. 2008:6580902008. View Article : Google Scholar
10	Cassier PA, Dufresne A, Blay JY and Fayette J: Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag. 4:109–116. 2008.
11	ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7): vii92–vii99. 2012.
12	Carter NJ and Keam SJ: Trabectedin: A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 67:2257–2276. 2007. View Article : Google Scholar
13	Friedman D, Hu Z, Kolb EA, et al: Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 62:3377–3381. 2002.
14	D’Incalci M and Galmarini CM: A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 9:2157–2163. 2010.PubMed/NCBI
15	Demetri GD, Chawla SP, von Mehren M, et al: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol. 27:4188–4196. 2009. View Article : Google Scholar
16	Grosso F, Jones RL, Demetri GD, et al: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8:595–602. 2007. View Article : Google Scholar : PubMed/NCBI
17	Christinat A and Leyvraz S: Role of trabectedin in the treatment of soft tissue sarcoma. Onco Targets Ther. 2:105–113. 2009.PubMed/NCBI
18	Schöffski P, Wolter P, Clement P, et al: Trabectedin (ET-743): Evaluation of its use in advanced soft-tissue sarcoma. Future Oncol. 3:381–392. 2007.PubMed/NCBI